Skip to main content
UniHealth

Doctor search

Rajan P Kulkarni, MD

Dermatology · Portland

NPI 1902040777

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
Not verified
Not the same as out of network.
Offices
2

Offices

2 locations · University Professional Services · 1,683 clinicians in this group

Looking this up.

Hospitals listed: OHSU Hospital and Clinics. That is not proof they admit you there this week.

Plan participation

Not verified

We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kulkarni’s office to ask if they take your plan before you enroll.

California Medical Board record

Licence A113764 · Current

Licensed to practise in California · since 2010 · expires 2028-05-31 · University of California, Los Angeles School of Medicine.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • OHSU Hospital and ClinicsPortland, ORAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Oregon Health and Science University, which runs 2 hospitalsHome of Knight Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 76% would definitely recommend it
    Overall rating: 3 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.31 (1.1 to 1.51), Jul 2022 – Jun 2024Worse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 6.83 (5.37 to 8.29) · 3,784 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.733, Oct 2024 – Sep 2025
See every measure and the patient survey for OHSU Hospital and Clinics

Behind the star rating — Deaths: 0 better, 7 the same, 0 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at OHSU Hospital and Clinics
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.31 (1.1 to 1.51)WorseJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths6.83 (5.37 to 8.29) · 3,784 casesWorseJul 2022 – Jun 2024
Clostridium Difficile (C.Diff)Infections0.733BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.38 (0.61 to 2.14) · 2,275 casesNo differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths150.45 (118.94 to 181.96) · 340 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths3 · 44 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths11.3 · 98 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths10.6 · 197 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths14.7 · 145 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths11.7 · 273 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.4 · 3,434 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.25 (0.07 to 0.43) · 7,501 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.24 (0.06 to 0.42) · 7,980 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths2.42 (1.27 to 3.57) · 2,337 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.27 (1.24 to 3.31) · 3,615 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths10.99 (7.55 to 14.42) · 2,153 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths7.35 (5.23 to 9.48) · 2,355 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.98 (0.69 to 3.27) · 1,001 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.66 (0.18 to 1.14) · 6,661 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.2 · 56 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.838No differentOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.8No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.936No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections1.381No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.174No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits14.7 · 180 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.3 · 320 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits11.9 · 120 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits7.9 · 223 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits24.5 · 142 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits15.6 · 204 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5 (3.9 to 6.3) · 952 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits9.5 (8 to 11.4) · 952 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.8 · 47 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.4 · 88 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 49 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits11.8 (9.1 to 15.4) · 1,483 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.7 to 1.1) · 1,425 casesNo differentJan 2024 – Dec 2024

What patients said (812 patients answered, 24% of those asked)

Patient survey stars by topic at OHSU Hospital and Clinics
Cleanliness2
Nurse communication4
Doctor communication3
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness3
Recommend hospital4
Share of patients giving the best answer at OHSU Hospital and Clinics
Room was "always" clean64%
Nurses "always" communicated well80%
Doctors "always" communicated well78%
Staff "always" explained62%
Yes, staff "did" give patients this information87%
Yes, staff "did" give patients information about help after discharge85%
Doctors "always" explained things so they could understand72%
Doctors "always" listened carefully78%
Doctors "always" treated them with courtesy and respect84%
Patients who gave a rating of "9" or "10" (high)70%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand76%
Nurses "always" listened carefully76%
Nurses "always" treated them with courtesy and respect87%
"Always" quiet at night51%
"YES", patients would definitely recommend the hospital76%
Staff "always" explained possible side effects49%
Yes, staff "did" give patients information about possible symptoms89%

Original Medicare doctor bills

$3,693

Medicare paid this office $3,693 for 21 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Return visit (30+ min)18$2,026$81
Destruction of precancer skin growth, 1 growth12$744$44

Procedures Medicare counted

Procedure volume Medicare published
Removal of skin lesions33More than 69% of doctors who do this
Removal or shaving of skin growth1-10None
Skin biopsy13More than 61% of doctors who do this

Who their Medicare patients are

21 Original Medicare patients in 2024. Average age 63 · 85 and older 0% · Health risk score 3.73. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.

Conditions among them: High blood pressure 75% · Chronic kidney disease 62%.

The office billed $20,784, Medicare allowed $4,679 and paid $3,693; for 163 services of 11 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
202421163633.73$20,784$3,693
202328181662.84$25,469$4,809
202229115642.67$19,217$3,691
20201149701.49$4,652$944
2017127362741.80$84,051$13,688
201688267722.04$53,478$7,650
201576191722.24$45,976$6,742
20143297722.04$19,571$3,257

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 4 services

Original Medicare services billed in 2023
Return visit (30+ min)23$2,309$80
Destruction of precancer skin growth, 1 growth18$877$40
Biopsy of related skin growth, first growth13$278$20
Destruction of precancer skin growth, 2-14 growths14$151$2

2022: 2 services

Original Medicare services billed in 2022
Return visit (30+ min)18$1,522$80
Destruction of precancer skin growth, 1 growth13$524$40

2017: 7 services

Original Medicare services billed in 2017
Short return visit (20+ min)66$4,048$60
Biopsy of single growth of skin and/or tissue20$1,647$82
Destruction of skin growth, 1-14 growths12$1,300$100
Short return visit (20+ min)24$1,099$33
New patient visit (30+ min)12$829$69
Destruction of precancer skin growth, 1 growth20$798$40
Destruction of precancer skin growth, 2-14 growths19$561$5

2016: 6 services

Original Medicare services billed in 2016
Short return visit (20+ min)40$1,679$34
New patient visit (30+ min)21$1,261$60
Destruction of precancer skin growth, 1 growth19$907$41
Biopsy of single growth of skin and/or tissue22$658$27
Destruction of skin growth, 1-14 growths12$625$52
Destruction of precancer skin growth, 2-14 growths14$154$2

2015: 4 services

Original Medicare services billed in 2015
New patient visit (30+ min)27$1,561$58
Short return visit (20+ min)36$1,554$36
Destruction of skin growth, 1-14 growths17$998$55
Biopsy of single growth of skin and/or tissue12$336$28

2014: 2 services

Original Medicare services billed in 2014
New patient visit (30+ min)11$703$64
Short return visit (20+ min)12$558$43

Money from drug and device companies

$35 in 2024

Industry payments by year
202411None$35
202311None$5
202111$2,480$2,480
201915None$376

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
Merck Sharp & DohmeNone$35
1 payment
  • Meals · 2024-04-23 · $35
See the published payment
Every published payment
Merck Sharp & DohmeMeals · 2024-04-23None$35
See earlier years (2023, 2021, 2019)

2023: $5

Payments by company in 2023
Merck Sharp & DohmeNone$5
1 payment
  • Meals · 2023-11-14 · $5

2021: $2,480

Payments by company in 2021
Regeneron PharmaceuticalsLibtayo$2,480
1 payment
  • Consulting for Libtayo · 2021-01-29 · $2,480

2019: $376

Payments by company in 2019
GenzymeNo Product Discussed$376
5 payments
  • Travel for No Product Discussed · 2019-10-24 · $60
  • Travel for No Product Discussed · 2019-10-24 · $24
  • Meals for No Product Discussed · 2019-10-24 · $127
  • Travel for No Product Discussed · 2019-10-24 · $6
  • Travel for No Product Discussed · 2019-10-24 · $160

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Regeneron Pharmaceuticals, Inc. · Cemiplimab Survivorship Epidemiology (Case) Study · 2021Their institution$13,387
Regeneron Pharmaceuticals, Inc. · Cemiplimab Survivorship Epidemiology (Case) Study · 2024Their institution$4,352
Regeneron Pharmaceuticals, Inc. · Cemiplimab Survivorship Epidemiology (Case) Study · 2023Their institution$4,160
Regeneron Pharmaceuticals, Inc. · Cemiplimab Survivorship Epidemiology (Case) Study · 2022Their institution$4,150
Regeneron Pharmaceuticals, Inc. · Cemiplimab Survivorship Epidemiology (Case) Study · 2025Their institution$4,109
Regeneron Pharmaceuticals, Inc. · A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (Cscc) · 2025This clinician$1,322

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
97.8 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1902040777
Licence
CA A113764, OR MD186821California A113764: Current · expires 2028-05-31
Trained
University of California, Geffen School of Medicine, 2009
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207N00000X (207N00000X); Student in a training program (390200000X)
Mailing address
3303 Sw Bond Ave Ste 16, Portland, OR, 97239
NPI first listed
2009-04-23
NPI last updated
2018-07-13

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 200 Med Plaza Bldg 465, Los Angeles, CA, 90095 · 751 S Bascom Ave, San Jose, CA, 95128